Free Trial

Immunovant (IMVT) Competitors

$25.17
-0.26 (-1.02%)
(As of 06/7/2024 ET)

IMVT vs. UTZ, VVNT, ADV, CCIV, MPLN, NBIX, TECH, QGEN, RGEN, and PCVX

Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Utz Brands (UTZ), Vivint Smart Home (VVNT), Advantage Solutions (ADV), Churchill Capital Corp IV (CCIV), MultiPlan (MPLN), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), and Vaxcyte (PCVX).

Immunovant vs.

Utz Brands (NYSE:UTZ) and Immunovant (NASDAQ:IMVT) are both mid-cap consumer staples companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk.

Utz Brands has higher revenue and earnings than Immunovant. Utz Brands is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utz Brands$1.43B1.81-$24.94M-$0.25-73.72
ImmunovantN/AN/A-$259.34M-$1.90-13.25

Immunovant has a net margin of 0.00% compared to Immunovant's net margin of -1.38%. Immunovant's return on equity of 6.16% beat Utz Brands' return on equity.

Company Net Margins Return on Equity Return on Assets
Utz Brands-1.38% 6.16% 3.15%
Immunovant N/A -53.40%-48.85%

Immunovant received 61 more outperform votes than Utz Brands when rated by MarketBeat users. Likewise, 76.71% of users gave Immunovant an outperform vote while only 60.00% of users gave Utz Brands an outperform vote.

CompanyUnderperformOutperform
Utz BrandsOutperform Votes
51
60.00%
Underperform Votes
34
40.00%
ImmunovantOutperform Votes
112
76.71%
Underperform Votes
34
23.29%

Utz Brands has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

In the previous week, Immunovant had 8 more articles in the media than Utz Brands. MarketBeat recorded 15 mentions for Immunovant and 7 mentions for Utz Brands. Immunovant's average media sentiment score of 0.99 beat Utz Brands' score of 0.68 indicating that Utz Brands is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Utz Brands
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunovant
6 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.0% of Utz Brands shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 17.0% of Utz Brands shares are held by insiders. Comparatively, 4.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Utz Brands currently has a consensus price target of $20.42, suggesting a potential upside of 10.78%. Immunovant has a consensus price target of $48.75, suggesting a potential upside of 93.68%. Given Utz Brands' stronger consensus rating and higher possible upside, analysts plainly believe Immunovant is more favorable than Utz Brands.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Utz Brands
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75
Immunovant
0 Sell rating(s)
0 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Utz Brands beats Immunovant on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMVT vs. The Competition

MetricImmunovantBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.68B$2.92B$5.26B$8.17B
Dividend YieldN/A2.28%2.74%4.04%
P/E Ratio-13.2527.81140.1218.13
Price / SalesN/A250.472,403.0666.88
Price / CashN/A164.9535.3931.03
Price / Book5.924.384.984.32
Net Income-$259.34M-$46.10M$110.61M$216.21M
7 Day Performance-0.87%-0.30%-1.08%-1.44%
1 Month Performance-15.42%-2.07%-0.68%-0.60%
1 Year Performance18.45%-3.78%2.90%3.53%

Immunovant Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UTZ
Utz Brands
3.6485 of 5 stars
$18.48
+0.6%
$20.42
+10.5%
+12.7%$2.60B$1.44B-73.903,654Dividend Announcement
News Coverage
Positive News
VVNT
Vivint Smart Home
0 of 5 stars
$12.00
flat
N/A+0.0%$2.58B$1.68B-50.0011,000High Trading Volume
ADV
Advantage Solutions
0.7307 of 5 stars
$2.87
-11.6%
$3.43
+19.8%
+44.5%$1.04B$4.16B-40.9270,000
CCIV
Churchill Capital Corp IV
0 of 5 stars
$2.85
+0.7%
N/A-56.5%$737.44MN/A0.00147,000
MPLN
MultiPlan
0.3693 of 5 stars
$0.47
-6.0%
$2.00
+324.5%
-76.1%$303.80M$961.52M-0.482,800Gap Down
NBIX
Neurocrine Biosciences
4.7198 of 5 stars
$133.48
-4.6%
$150.85
+13.0%
+43.5%$13.43B$1.89B36.771,400
TECH
Bio-Techne
3.9467 of 5 stars
$76.90
-1.3%
$81.00
+5.3%
-2.1%$12.12B$1.14B61.033,050Positive News
QGEN
Qiagen
4.0929 of 5 stars
$43.67
-0.8%
$50.95
+16.7%
-4.3%$9.97B$1.97B29.285,967
RGEN
Repligen
4.4445 of 5 stars
$147.75
-1.7%
$197.75
+33.8%
-11.2%$8.26B$638.76M591.021,783Positive News
PCVX
Vaxcyte
0.3373 of 5 stars
$70.94
-1.8%
$78.50
+10.7%
+39.3%$7.72BN/A-16.57254Insider Selling
News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:IMVT) was last updated on 6/9/2024 by MarketBeat.com Staff

From Our Partners